AstraZeneca (AZ) has announced first-half 2026 total revenue of USD 30.7 billion, up 6% year-on-year, with product sales of USD 30.6 billion. By region, the US contributed USD 12.9 billion (+8%), whilst China declined 5% to USD 3.5 billion, representing 11% of the global mix.

Therapeutic area performance was led by oncology at USD 14.1 billion (+15%), followed by cardiovascular, renal, and metabolism (CVRM) at USD 6.0 billion (-12%), rare disease at USD 4.9 billion (+11%), and respiratory and immunology at USD 4.8 billion (+9%). The CVRM decline was driven by Farxiga (dapagliflozin) erosion (-11%) from US and Japanese generics plus Chinese centralised procurement.

Key growth drivers included Imfinzi (durvalumab) at USD 3.6 billion (+29%), Enhertu (trastuzumab deruxtecan) with USD 1.7 billion in recognised revenue for AZ (+32%), Tagrisso (osimertinib) at USD 3.8 billion (+6%), and Tezspire (tezepelumab) at USD 694 million (+40%).

Six Phase III readouts were positive, spanning liver cancer (EMERALD-3), bladder cancer (VOLGA), Claudin 18.2 gastric cancer (CLARITY-Gastric01), COPD (OBERON/TITANIA/MIRANDA for tozorakimab), IgA nephropathy (I CAN for Ultomiris), and hypophosphatasia (HICKORY/CHESTNUT/MULBERRY for efzimfotase alfa).

AZ guided mid-to-high single-digit full-year revenue growth.